6 completed, 6 terminated, 5 recruiting, 5 withdrawn. 15 Phase 1, 15 Phase 2, 2 Phase 3, 1 Not applicable.
Follow Castrate Resistant Prostate Cancer: new trials by email Literature Review of Castrate Resistant Prostate Cancer trials Research Report on Castrate Resistant Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas DR-0202 - Triple Negative Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Recruiting | Dren Bio | 96 | 2025-06-03 | 2026-01-07 |
| Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer Niraparib/Abirate rone acetate fixed-dose combination, Prednisone - Prostate Cancer, Castrate Resistant Prostate Cancer | Phase 2 | Withdrawn | Latin American Cooperative Oncology Group | 2025-04-30 | 2025-09-29 | |
| Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage Enzalutamide 40 MG, Docetaxel injection - Prostate Cancer, Castrate Resistant Prostate Cancer | Phase 2 / Phase 3 | Unknown | Zhongnan Hospital | 120 | 2024-06-01 | 2024-02-28 |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies ETX-19477 - Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1 / Phase 2 | Recruiting | 858 Therapeutics, Inc. | 120 | 2024-05-13 | 2026-03-27 |
| 177Lu-HTK03170 in mCRPC With PSMA Positive Disease 177Lu HTK03170, 68Ga-HTK03149 - Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic | Phase 1 / Phase 2 | Enrolling by invitation | British Columbia Cancer Agency | 50 | 2024-01-01 | 2026-01-08 |
| Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer Pembrolizumab, 177Lu-PSMA-617 - Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | University of California, San Francisco | 48 | 2023-12-15 | 2026-09-10 |
| Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients High Intensity Interval Training - Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer | Not applicable | Withdrawn | The University of Texas Health Science Center at San Antonio | 2023-12-01 | 2024-02-26 | |
| TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma TT-10, TT-4 - Renal Cell Cancer, Castrate Resistant Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Portage Biotech | 35 | 2023-06-23 | 2026-09-15 |
| Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers Regorafenib in combination with Tislelizumab - Anal Squamous Cell Carcinoma, Colorectal Neoplasms | Phase 2 | Withdrawn | Translational Research in Oncology | 2023-04-30 | 2023-06-07 | |
| Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer Olaparib - Prostate Cancer, Castrate Resistant Prostate Cancer | Recruiting | Santa Chiara Hospital | 3000 | 2023-01-01 | 2025-02-11 | |
| Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies EP31670 - Castrate Resistant Prostate Cancer, NUT Carcinoma | Phase 1 | Unknown | Epigenetix, Inc. | 75 | 2022-12-21 | 2025-01-14 |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas APG-5918 - Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer | Phase 1 | Unknown | Ascentage Pharma Group Inc. | 90 | 2022-09-30 | 2022-11-16 |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC NUV-422, Enzalutamide - Prostate Cancer, Prostatic Cancer | Phase 1 / Phase 2 | Withdrawn | Nuvation Bio Inc. | 2022-09-01 | 2022-08-05 | |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868, Olaparib, Enzalutamide - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Terminated | Nuvation Bio Inc. | 82 | 2022-03-29 | 2025-11-06 |
| A Study of PRT2527 in Participants With Advanced Solid Tumors PRT2527 - Sarcoma, Castrate Resistant Prostate Cancer | Phase 1 | Completed | Prelude Therapeutics Incorporated | 30 | 2022-02-14 | 2023-12-11 |
| Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide Darolutamide, Enzalutamide - Metastatic Prostate Cancer, Prostate Cancer Metastatic | Phase 2 | Completed | Alliance Foundation Trials, LLC. | 111 | 2021-08-17 | 2026-09-21 |
| Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer Ipatasertib, Darolutamide, Androgen Deprivation Therapy - Castrate Resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | David VanderWeele | 6 | 2021-07-13 | 2023-11-13 |
| Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA Darolutamide, Radiotherapy - Advanced Prostate Carcinoma, Cancer of Prostate | Phase 2 | Active not recruiting | Trans Tasman Radiation Oncology Group | 65 | 2021-06-02 | 2025-08-21 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NUV-422 - Glioma, Glioma, Malignant | Phase 1 | Terminated | Nuvation Bio Inc. | 74 | 2020-12-08 | 2023-07-14 |
| Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone Abiraterone Acetate, Sodium Selenite, Prednisone - Prostate Cancer, Castrate Resistant Prostate Cancer | Phase 1 | Withdrawn | Stanford University | 2020-10-01 | 2021-08-12 |
Showing 20 of 27. Sign in to see all of them.
Prostatic Neoplasms (18) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Ovarian Neoplasms (3) · Prostatic Neoplasms, Castration-Resistant (3) · Sarcoma (3) · Stomach Neoplasms (3) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Mesothelioma, Malignant (2) · Triple Negative Breast Neoplasms (2) · Anus Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1)
Neoplasms (22) · Neoplasms by Site (22) · Urogenital Diseases (20) · Urogenital Neoplasms (20) · Genital Diseases (19) · Male Urogenital Diseases (19) · Genital Diseases, Male (18) · Genital Neoplasms, Male (18) · Prostatic Diseases (18) · Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (6) · Breast Diseases (5) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Skin Diseases (5)
enzalutamide (4) · darolutamide (3) · Ipilimumab (2) · Prednisone (2) · olaparib (2) · 1-(1-((5-methoxy-1H-indol-2-yl)carbonyl)piperidin-4-yl)-2-methylpropan-2-ol (1) · Abiraterone Acetate (1) · Androgen Antagonists (1) · Biopsy (1) · Docetaxel (1) · Everolimus (1) · High-Intensity Interval Training (1) · Lenograstim (1) · Melphalan (1) · NEO2734 (1)
Nuvation Bio Inc. (3) · 858 Therapeutics, Inc. (1) · Alliance Foundation Trials, LLC. (1) · Ascentage Pharma Group Inc. (1) · Astellas Pharma Inc (1) · Barts & The London NHS Trust (1) · British Columbia Cancer Agency (1) · Daniel Vaena (1) · David VanderWeele (1) · Dren Bio (1) · Epigenetix, Inc. (1) · Herlev and Gentofte Hospital (1) · Latin American Cooperative Oncology Group (1) · Portage Biotech (1) · Prelude Therapeutics Incorporated (1)
United States (16) · Australia (2) · United Kingdom (2) · Belgium (1) · Canada (1) · China (1) · Denmark (1) · France (1) · Italy (1) · Netherlands (1) · Singapore (1)
Arun Azad (1) · Daniel McCormick (1) · Daniel Vaena, MD (1) · Darpan I Patel, PhD (1) · David VanderWeele, MD\Phd (1) · Evanthia Galanis, MD (1) · Fernando Cotait Maluf (1) · Inge M. van Oort, MD, PhD (1) · Jianqing Lin, MD (1) · Jonathan Shamash, MD FRCP (1) · Josep Tabernero (1) · Judy Chiao, MD (1) · Mark Scholz, MD (1) · Rahul Aggarwal, MD (1) · Rikke HL Eefsen, MD, PhD (1)
PMID 24771350, PMID 35804188, PMID 36125208, PMID 36717150, PMID 40306965, PMID 42493213